Table 1.
Examples of incretin-based therapies
| Drug | Manufacturer | Availability |
|---|---|---|
| DPP-IV inhibitors | ||
| Linagliptin | Boehringer Ingelheim | Currently in phase III |
| Dutogliptin | Phenomix Corporation | Currently in phase III |
| Alogliptin | Takeda Pharmaceuticals Company | Currently in phase III |
| Sitagliptin | Merck & Co. | Available in US, Europe, and Japan |
| Saxagliptin | Bristol-Myers Squibb | Available in US, Europe, and Japan |
| Vildagliptin | Novartis | Available in Europe and Australia |
| GLP-1 receptor agonists | ||
| Albiglutide | GlaxoSmithKline | Currently in phase III |
| Taspoglutide | Ipsen and Roche | Currently in phase III |
| Lixasenatide | Sanofi-Aventis | Currently in phase III |
| Exenatide | Amylin Pharmaceuticals and Eli Lilly and Company | Available in US, Europe, and Japan |
| Liraglutide | Novo Nordisk | Available in US, Europe, and Japan |
DPP-IV dipeptidyl-peptidase-IV; GLP-1 glucagon-like peptide 1